Skip to content

Ureteral Stent Exchange Abstention in Urinary Tract Infections

Ureteral Stent Exchange Abstention in Urinary Tract Infections: a Before-and-after Study to Assess Guidelines' Impact on Patients' Outcomes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06503588
Acronym
JJ-change-UTI
Enrollment
300
Registered
2024-07-16
Start date
2024-07-01
Completion date
2025-09-01
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Catheterization, Urinary Tract Infections

Brief summary

The Committee of Infectiology of the French Association of Urology (CIAFU) provided, for the first time in 2020, comprehensive guidelines for ureteral stent-associated urinary tract infections (USAUTI) prevention, diagnosis and treatment. Since evidence lacked in terms of appropriate treatment, guidelines could not support systematic change of US in case of USAUTI. This study aims to evaluate whether after guidelines group patients treated for USAUTI had different occurrence of at least one relapse or recurrence than before guidelines group.

Interventions

OTHERGuidelines promoting surgical abstention

Guidelines promoting surgical abstention

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All patients with indwelling ureteral catheter * AND confirmed or probable urinary tract infection

Exclusion criteria

* Patient's opposition * History of ileal conduit urinary diversion * Second or more urinary tract infection during the study period

Design outcomes

Primary

MeasureTime frame
Relapse OR recurrence of urinary tract infection1 year

Secondary

MeasureTime frameDescription
Nephro-urologic complication1 yearAcute kidney injury ; hematuria ; pain ; stent migration or incrustation
Infectious complication1 yearSepsis or septic shock
In-hospital and 1-year mortality1 yearall cause death
Resort to Watch or Reserve antibiotics1 yearantibiotics' WHO classifcation

Countries

France

Contacts

Primary ContactBenjamin Lefevre, M.D. PhD
b.lefevre@chru-nancy.fr+33383154097
Backup ContactTahani Sara
s.tahani@chru-nancy.fr+33383154097

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026